CL2009000229A1 - Compuestos derivados de piridinona y piridazinona, inhibidores de btk; composicion farmaceutica que comprenden dichos compuestos; y uso para el tratamiento de enfermedades inflamatorias y/o autoinmunes como artritis, entre otras. - Google Patents
Compuestos derivados de piridinona y piridazinona, inhibidores de btk; composicion farmaceutica que comprenden dichos compuestos; y uso para el tratamiento de enfermedades inflamatorias y/o autoinmunes como artritis, entre otras.Info
- Publication number
- CL2009000229A1 CL2009000229A1 CL2009000229A CL2009000229A CL2009000229A1 CL 2009000229 A1 CL2009000229 A1 CL 2009000229A1 CL 2009000229 A CL2009000229 A CL 2009000229A CL 2009000229 A CL2009000229 A CL 2009000229A CL 2009000229 A1 CL2009000229 A1 CL 2009000229A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- inflammatory
- arthritis
- pyridinone
- pyridazinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ESTA SOLICITUD SE REFIERE A DERIVADOS DE 5-FENIL- L H-PIRIDIN-2-ONA Y 6-FENIL-2H-PIRIDAZIN-3-ONA DE LAS FÓRMULAS GENÉRICAS 1- 111: EN LAS QUE LAS VARIABLES R, X, Y1• Y2, Y3, Y4, N Y M TIENEN LOS SIGNIFICADOS DEFINIDOS ANTERIORMENTE. LOS COMPUESTOS AQUÍ DESCRITOS SON ÚTILES PARA MODULAR LA ACTIVIDAD DE LA BTK Y TRATAR ENFERMEDADES ASOCIADAS CON UNA ACTIVIDAD EXCESIVA DE LA BTK. ADEMÁS, ESTOS COMPUESTOS SON ÚTILES PARA TRATAR ENFERMEDADES INFLAMATORIAS Y AUTOINRNUNES ASOCIADAS CON LA PROLIFERACIÓN ABERRANTE DE CÉLULAS B, COMO LA ARTRITIS REUMATOIDE. SE DESCRIBEN TAMBIÉN COMPOSICIONES QUE CONTIENEN LOS COMPUESTOS DE LAS FÓRMULAS 1-111 Y POR LO MENOS UN VEHLCULO, DILUYENTE O EXCIPIENTE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2620408P | 2008-02-05 | 2008-02-05 | |
US12251008P | 2008-12-15 | 2008-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000229A1 true CL2009000229A1 (es) | 2010-06-04 |
Family
ID=40413736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000229A CL2009000229A1 (es) | 2008-02-05 | 2009-02-03 | Compuestos derivados de piridinona y piridazinona, inhibidores de btk; composicion farmaceutica que comprenden dichos compuestos; y uso para el tratamiento de enfermedades inflamatorias y/o autoinmunes como artritis, entre otras. |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP2242749B1 (es) |
JP (1) | JP5259739B2 (es) |
KR (1) | KR101308803B1 (es) |
CN (1) | CN101932573B (es) |
AR (1) | AR070408A1 (es) |
AU (1) | AU2009211514B2 (es) |
BR (1) | BRPI0907915A2 (es) |
CA (1) | CA2710462C (es) |
CL (1) | CL2009000229A1 (es) |
CO (1) | CO6290767A2 (es) |
CR (1) | CR11598A (es) |
CY (1) | CY1114114T1 (es) |
DK (1) | DK2242749T3 (es) |
EC (1) | ECSP10010384A (es) |
ES (1) | ES2420846T3 (es) |
HK (1) | HK1146826A1 (es) |
HR (1) | HRP20130615T1 (es) |
IL (1) | IL206357A (es) |
MA (1) | MA32064B1 (es) |
MX (1) | MX2010008197A (es) |
MY (1) | MY158411A (es) |
NZ (1) | NZ586916A (es) |
PE (1) | PE20091484A1 (es) |
PL (1) | PL2242749T3 (es) |
PT (1) | PT2242749E (es) |
RU (1) | RU2505538C2 (es) |
SI (1) | SI2242749T1 (es) |
TW (1) | TWI382024B (es) |
WO (1) | WO2009098144A1 (es) |
ZA (1) | ZA201005539B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102066366B (zh) | 2008-06-24 | 2014-04-16 | 霍夫曼-拉罗奇有限公司 | 新型取代的吡啶-2-酮和哒嗪-3-酮 |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CN102292329B (zh) * | 2009-04-24 | 2014-09-03 | 霍夫曼-拉罗奇有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
EP2473049B1 (en) | 2009-09-04 | 2018-11-28 | Biogen MA Inc. | Bruton's tyrosine kinase inhibitors |
RU2017112518A (ru) * | 2010-05-07 | 2019-01-25 | Джилид Коннектикут, Инк. | Пиридоновые и азапиридоновые соединения и способы применения |
EP2394998A1 (en) * | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
AU2012257802A1 (en) * | 2011-05-17 | 2013-10-31 | F. Hoffmann-La Roche Ag | Inhibitors of Bruton's tyrosine kinase |
MX349372B (es) * | 2011-08-17 | 2017-07-26 | Hoffmann La Roche | Inhibidores de la tirosina-cinasa de bruton. |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
CN104244939A (zh) | 2012-04-05 | 2014-12-24 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法 |
AU2013250726B2 (en) | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
US9499548B2 (en) * | 2012-09-13 | 2016-11-22 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
WO2014076104A1 (en) * | 2012-11-16 | 2014-05-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
WO2014083026A1 (en) * | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
KR101737724B1 (ko) * | 2013-03-05 | 2017-05-29 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
CN105143215B (zh) * | 2013-03-05 | 2017-12-08 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
DK2989106T3 (en) | 2013-04-25 | 2017-03-20 | Beigene Ltd | CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS |
CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
CN110698481B (zh) * | 2013-07-03 | 2023-02-28 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
EP3077384B1 (en) * | 2013-12-05 | 2017-09-06 | F. Hoffmann-La Roche AG | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
WO2016050921A1 (en) * | 2014-10-02 | 2016-04-07 | F. Hoffmann-La Roche Ag | Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk) |
EP3402789B1 (en) * | 2016-01-13 | 2020-03-18 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
US20190105407A1 (en) | 2016-03-31 | 2019-04-11 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
US11174243B2 (en) | 2016-07-21 | 2021-11-16 | Sunesis Pharmaceuticals, Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
MX2019001900A (es) | 2016-08-16 | 2019-07-01 | Beigene Ltd | Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxife nil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma. |
CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
MA46285A (fr) | 2016-09-19 | 2019-07-31 | Mei Pharma Inc | Polythérapie |
TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
CN106967073A (zh) * | 2017-04-24 | 2017-07-21 | 刘双伟 | 一种治疗类风湿性关节炎的药物 |
CN108164536A (zh) * | 2017-05-08 | 2018-06-15 | 刘双伟 | 一种用于治疗类风湿性关节炎的新的化合物的合成方法 |
AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
WO2020081450A1 (en) | 2018-10-15 | 2020-04-23 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
US11530229B2 (en) | 2019-05-17 | 2022-12-20 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021091575A1 (en) * | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
AU2020397920A1 (en) | 2019-12-04 | 2022-06-16 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CA3214729A1 (en) | 2021-04-08 | 2022-10-13 | Marilena GALLOTTA | Combination therapies with cbl-b inhibitor compounds |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3951395B2 (ja) * | 1996-12-13 | 2007-08-01 | 田辺製薬株式会社 | ピリジン誘導体、その製法及びその合成中間体 |
NZ514711A (en) * | 1999-03-12 | 2004-02-27 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
EP1831168B1 (en) * | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
JP4937135B2 (ja) * | 2004-12-24 | 2012-05-23 | アストラゼネカ・アクチエボラーグ | アミド誘導体 |
EP1863766B1 (en) * | 2005-03-10 | 2015-05-20 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
WO2006124731A2 (en) * | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US7868018B2 (en) * | 2005-08-09 | 2011-01-11 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AU2006285038A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
BRPI0711628A2 (pt) * | 2006-05-15 | 2011-12-06 | Irm Llc | composto, composição farmacêutica, uso e processo para preparação do composto |
-
2009
- 2009-01-27 JP JP2010545433A patent/JP5259739B2/ja not_active Expired - Fee Related
- 2009-01-27 PT PT97091359T patent/PT2242749E/pt unknown
- 2009-01-27 NZ NZ586916A patent/NZ586916A/en not_active IP Right Cessation
- 2009-01-27 CA CA2710462A patent/CA2710462C/en not_active Expired - Fee Related
- 2009-01-27 WO PCT/EP2009/050875 patent/WO2009098144A1/en active Application Filing
- 2009-01-27 RU RU2010136665/04A patent/RU2505538C2/ru not_active IP Right Cessation
- 2009-01-27 AU AU2009211514A patent/AU2009211514B2/en not_active Expired - Fee Related
- 2009-01-27 SI SI200930630T patent/SI2242749T1/sl unknown
- 2009-01-27 EP EP09709135.9A patent/EP2242749B1/en not_active Not-in-force
- 2009-01-27 BR BRPI0907915-7A patent/BRPI0907915A2/pt not_active IP Right Cessation
- 2009-01-27 MY MYPI2010003693A patent/MY158411A/en unknown
- 2009-01-27 PL PL09709135T patent/PL2242749T3/pl unknown
- 2009-01-27 MX MX2010008197A patent/MX2010008197A/es active IP Right Grant
- 2009-01-27 ES ES09709135T patent/ES2420846T3/es active Active
- 2009-01-27 CN CN200980103857.3A patent/CN101932573B/zh not_active Expired - Fee Related
- 2009-01-27 KR KR1020107016014A patent/KR101308803B1/ko not_active IP Right Cessation
- 2009-01-27 DK DK09709135.9T patent/DK2242749T3/da active
- 2009-02-03 CL CL2009000229A patent/CL2009000229A1/es unknown
- 2009-02-03 AR ARP090100345A patent/AR070408A1/es not_active Application Discontinuation
- 2009-02-03 TW TW098103399A patent/TWI382024B/zh not_active IP Right Cessation
- 2009-02-04 PE PE2009000169A patent/PE20091484A1/es not_active Application Discontinuation
-
2010
- 2010-06-14 IL IL206357A patent/IL206357A/en not_active IP Right Cessation
- 2010-07-26 CO CO10090865A patent/CO6290767A2/es active IP Right Grant
- 2010-07-27 CR CR11598A patent/CR11598A/es not_active Application Discontinuation
- 2010-08-03 ZA ZA2010/05539A patent/ZA201005539B/en unknown
- 2010-08-05 EC EC2010010384A patent/ECSP10010384A/es unknown
- 2010-08-06 MA MA33066A patent/MA32064B1/fr unknown
-
2011
- 2011-01-28 HK HK11100915.9A patent/HK1146826A1/xx not_active IP Right Cessation
-
2013
- 2013-07-02 HR HRP20130615AT patent/HRP20130615T1/hr unknown
- 2013-07-08 CY CY20131100576T patent/CY1114114T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000229A1 (es) | Compuestos derivados de piridinona y piridazinona, inhibidores de btk; composicion farmaceutica que comprenden dichos compuestos; y uso para el tratamiento de enfermedades inflamatorias y/o autoinmunes como artritis, entre otras. | |
CO6382183A2 (es) | Nuevas piridin -2-onas y piridazin -3-onas sustituidas | |
ECSP13012437A (es) | Inhibidores de la tirosina-quinasa de bruton | |
CL2010001641A1 (es) | Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras. | |
CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
CL2011000668A1 (es) | Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras. | |
SV2011003903A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes | |
ECSP13012967A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
UY31171A1 (es) | Anhídridos y polímeros de esteres borónicos cíclicos y acíclicos, sus enantiómeros, sus sales farmacéuticamente aceptables, composiciones conteniéndolos y aplicaciones. | |
ECSP13012499A (es) | Nuevos compuestos | |
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
ATE482209T1 (de) | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität | |
CL2009000860A1 (es) | Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer. | |
CL2008003698A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina, inhibidores de la btk; composicion farmaceutica que los comprende; y uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune tal como la artritis reumatoide. | |
ECSP109879A (es) | Compuestos y metodos para modular el receptor | |
UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
CL2011003082A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
ECSP14013212A (es) | Inhibidores de la tirosina-quinasa de bruton | |
UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
GT201200242A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
CO6690805A2 (es) | 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3 |